Avalo Therapeutics, Inc. (AVTX) Stock AnalysisAVTXAvalo Therapeutics, Inc.

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Avalo Therapeutics is currently not a strong buy due to its recent price decline and negative financials. The current price is $11.27, with a significant 5-day change of -17.44%. While the gross margin stands at a solid 54.69%, the company has reported consistent losses, with a net income of -$36,358,000 in Q2 2026. The RSI is at a low 12.546, indicating oversold conditions, but the risk of further declines remains high given the insider selling activity increasing by 727.94%.